
PROTEIN AND PEPTIDE MASS SPECTROMETRY IN DRUG DISCOVERY

Edited By

Michael L. Gross

Washington University

Guodong Chen

Bristol-Myers Squibb

Birendra N. Pramanik

Merck Research Laboratories

 **WILEY**

A JOHN WILEY & SONS, INC., PUBLICATION

CONTENTS

PREFACE	xv
CONTRIBUTORS	xvii
PART I METHODOLOGY	1
1 Ionization Methods in Protein Mass Spectrometry	3
<i>Ismael Cotte-Rodriguez, Yun Zhang, Zhixin Miao, and Hao Chen</i>	
1.1 History of the Development of Protein Mass Spectrometry	4
1.2 Laser-Based Ionization Methods for Proteins	5
1.2.1 Matrix-Assisted Laser Desorption/Ionization (MALDI)	5
1.2.2 Atmospheric Pressure Matrix-Assisted Laser Desorption/Ionization (AP-MALDI)	8
1.2.3 Surface-Enhanced Laser Desorption/Ionization (SELDI)	9
1.2.4 Nanostructure-Initiator Mass Spectrometry (NIMS)	11
1.3 Spray-Based Ionization Methods for Proteins	13
1.3.1 Electrospray Ionization (ESI)	13
1.3.2 Sonic Spray Ionization (SSI)	14
1.3.3 Electrosonic Spray Ionization (ESSI)	17
1.4 Ambient Ionization Methods	20
1.4.1 Desorption Electrospray Ionization (DESI)	21
1.4.2 Fused-Droplet Electrospray Ionization (FD-ESI)	24
1.4.3 Electrospray-Assisted Laser Desorption Ionization (ELDI)	27
1.4.4 Matrix-Assisted Laser Desorption Electrospray Ionization (MALDESI)	30
1.5 Conclusions	30
Acknowledgments	30
References	30
2 Ion Activation and Mass Analysis in Protein Mass Spectrometry	43
<i>Cheng Lin and Peter O'Connor</i>	
2.1 Introduction	43
2.1.1 Mass Accuracy	43
2.1.2 Mass Resolving Power	44

2.1.3	Mass Range	44
2.1.4	Scan Speed	45
2.1.5	Tandem MS Analysis	46
2.2	Ion Activation and Tandem MS Analysis	46
2.2.1	Introduction: Fragmentation in Protein MS	46
2.2.2	Collisional Activation Methods	48
2.2.3	Photodissociation	50
2.2.4	Electron-Induced Dissociation	55
2.2.5	Other Radical-Induced Fragmentation Methods	59
2.3	Mass Analyzers	59
2.3.1	Time-of-Flight Mass Analyzer	60
2.3.2	Quadrupole Mass Analyzer and Quadrupole Ion Trap	66
2.3.3	Fourier-Transform Ion Cyclotron Resonance Mass Spectrometer	73
2.3.4	Orbitrap	77
2.3.5	Ion-Mobility Instruments	80
	References	81
3	Target Proteins: Bottom-up and Top-down Proteomics	89
	<i>Michael Boyne and Ron Bose</i>	
3.1	Mass Spectral Approaches to Targeted Protein Identification	89
3.2	Bottom-up Proteomics	90
3.2.1	Peptide Mass Fingerprinting	91
3.2.2	Bottom-up Proteomics Using Tandem MS: GeLC-MS/MS and Shotgun Digests	91
3.2.3	GeLC-MS/MS	93
3.2.4	Shotgun Digest	94
3.3	Top-down Approaches	96
3.4	Next-Generation Approaches	98
	References	99
4	Quantitative Proteomics by Mass Spectrometry	101
	<i>Jacob Galan, Anton Iliuk, and W. Andy Tao</i>	
4.1	Introduction	101
4.2	In-Cell Labeling	105
4.2.1	¹⁵ N Metabolic Labeling	105
4.2.2	Stable Isotope Labeling by Amino Acid (SILAC)	106
4.3	Quantitation via Isotopic Labeling of Proteins	107
4.3.1	2D PAGE-Based Quantitation	108
4.3.2	Proteolytic Labeling Using ¹⁸ O Water	109
4.3.3	Quantitative Labeling by Chemical Tagging	110

4.4	Quantitation via Isotopic Labeling on Peptides	112
4.4.1	ICAT	112
4.4.2	iTRAQ	113
4.4.3	SoPIL	113
4.4.4	Absolute Quantitation	114
4.5	Label-Free Quantitation	116
4.6	Conclusions	119
	Acknowledgment	120
	References	120
5	Comparative Proteomics by Direct Tissue Analysis Using Imaging Mass Spectrometry	129
	<i>Michelle L. Reyzer and Richard M. Caprioli</i>	
5.1	Introduction	129
5.2	Conventional Comparative Proteomics	130
5.3	Comparative Proteomics Using Imaging MS	131
5.3.1	Biomarker Discovery: Breast Cancer	131
5.3.2	Biomarker Discovery: Toxicity	133
5.3.3	Correlating Drug and Protein Distributions	134
5.4	Conclusions	136
	Acknowledgments	137
	References	137
6	Peptide and Protein Analysis Using Ion Mobility–Mass Spectrometry	139
	<i>Jeffrey R. Enders, Michal Kliman, Sevugarajan Sundarapandian, and John A. McLean</i>	
6.1	Ion Mobility–Mass Spectrometry: Instrumentation and Separation Selectivity	139
6.1.1	Instrumentation	140
6.1.2	Separation Selectivity in Bioanalyses	145
6.2	Characterizing and Interpreting Peptide and Protein Structures	147
6.2.1	The Motion of Ions within Neutral Gases	147
6.2.2	Considerations for Calculating Collision Cross Sections	148
6.2.3	Computational Approaches for Interpretation of Structure	149
6.3	Applications of IM-MS to Peptide and Protein Characterizations	152
6.3.1	Fundamental Studies of Peptide and Protein Ion Structures	152
6.3.2	Studies in Structural Biology—Protein Complex Characterization	157
6.4	Future Directions	158
6.4.1	Applications	158
6.4.2	Instrumentation	159

Acknowledgments	159
References	160
7 Chemical Footprinting for Determining Protein Properties and Interactions	175
<i>Sandra A. Kerfoot and Michael L. Gross</i>	
7.1 Introduction to Hydrogen–Deuterium Exchange	175
7.1.1 Fundamentals of Hydrogen–Deuterium Amide Exchange in Proteins	176
7.1.2 EX1 and EX2 Rates of HDX	176
7.2 Experimental Procedures	178
7.2.1 Global Hydrogen–Deuterium Exchange	178
7.2.2 HDX at the Peptide Level	179
7.3 Mass Spectrometry-Based HDX in Practice	182
7.3.1 Protein–Ligand Interactions by Automated HDX	182
7.3.2 Solvent Accessibility by HDX and MALDI-TOF Mass Spectrometry	183
7.3.3 High-Throughput Screening of Protein Ligands by SUPREX	184
7.3.4 Functional Labeling and Multiple Proteases	188
7.3.5 PLIMSTEX: Application in Protein–DNA Interactions	188
7.3.6 HDX and Tandem Mass Spectrometry Analysis	191
7.3.7 Optimizing HDX with High Pressure	192
7.4 Protein Footprinting via Free-Radical Oxidation	193
7.4.1 Fenton Chemistry Oxidation	194
7.4.2 Radiolytic Generation of Hydroxyl Radicals	196
7.4.3 Fast Photochemical Oxidation of Proteins (FPOP)	197
7.4.4 SPROX: Stability of Proteins from Rates of Oxidation	198
7.5 Chemical Crosslinking	198
7.5.1 Drawbacks of Crosslinking	199
7.6 Selective and Irreversible Chemical Modification	201
7.6.1 Acetylation of Lysine	202
7.6.2 Thiol Derivatization of Cysteines	203
7.6.3 Footprinting FMO Protein in Photosynthetic Bacteria	203
7.6.4 Potential Pitfalls	205
7.7 Conclusion	205
References	206
8 Microwave Technology to Accelerate Protein Analysis	213
<i>Urooj A. Mirza, Birendra N. Pramanik, and Ajay K. Bose</i>	
8.1 Introduction	213
8.2 Microwave Technology	215

8.2.1	Application of Microwave Irradiation to Akabori Reaction	215
8.2.2	Protein Characterization by Microwave Irradiation and MS	216
8.2.3	Temperature and Microwave Irradiation Effects on the Enzyme in Protein Digestion	217
8.2.4	Use of Microwave Digestion of Proteins from SDS-PAGE Gels	219
8.2.5	Extraction of Intact Proteins from SDS-PAGE Using Microwave Irradiation	219
8.2.6	Application of Microwave-Assisted Proteolysis Using Trypsin-Immobilized Magnetic Silica Microspheres	220
8.2.7	Acid Hydrolysis of Proteins with Microwave Irradiation	221
8.2.8	Do Protein Denature During Microwave Irradiation?	222
8.3	Summary	224
	Acknowledgments	224
	References	224
9	Bioinformatics and Database Searching	231
	<i>Surendra Dasari and David L. Tabb</i>	
9.1	Overview	231
9.2	Introduction to Tandem Mass Spectrometry	231
9.2.1	Protein Sequencing	231
9.2.2	Peptide Fragmentation	232
9.3	Overview of Peptide Identification with Database Searching	234
9.4	MyriMatch-IDPicker Protein Identification Pipeline	235
9.4.1	Raw Data File Formats	235
9.4.2	Protein Sequence Databases	237
9.4.3	MyriMatch Database Search Engine	239
9.4.4	Peptide Identification Reporting	242
9.4.5	Post-processing of Search Results Using IDpicker	243
9.5	Results of a Shotgun Proteomics Study	246
9.6	Improvements to MyriMatch Database Search Engine	248
9.6.1	Parallel Processing	248
9.6.2	Protein Modification Analysis	249
9.7	Applications of MyriMatch-IDPicker Pipeline	250
9.7.1	Characterizing Protein-Protein Interactions	250
9.7.2	Characterizing Yeast Proteome on Diverse Instrument Platforms	250
9.7.3	Characterizing DNA-Protein Crosslinks	250

9.8	Conclusions	251
	Acknowledgments	251
	References	251

PART II Applications 253

10 Mass Spectrometry-Based Screening and Characterization of Protein–Ligand Complexes in Drug Discovery 255

Christine L. Andrews, Michael R. Ziebell, Elliott Nickbarg, and Xianshu Yang

10.1	Introduction	255
10.2	Affinity Selection Mass Spectrometry (AS-MS)	256
10.2.1	Direct Detection of Noncovalent Protein–Ligand Complexes	257
10.2.2	Indirect Detection of Noncovalent Protein–Ligand Complexes	258
10.3	Solution-Based AS-MS as Screening Technologies	258
10.3.1	Automated Ligand Identification System (ALIS)	259
10.3.2	SpeedScreen	263
10.3.3	Ultracentrifugation Coupled to Mass Spectrometry	264
10.3.4	Gel Filtration–MS Platform	264
10.3.5	Frontal Affinity Chromatography–Mass Spectrometry (FAC-MS)	265
10.3.6	Indirect Detection AS-MS	266
10.3.7	Emerging Technology	266
10.4	Gas-Phase Interactions	267
10.4.1	Ion-Mobility Mass Spectrometry (IMS)	269
10.4.2	Hydrogen–Deuterium Exchange (H/DX) (Including SUPREX and PLIMSTEX)	270
10.4.3	Crosslinking (Including Inhibition of Complex Formation)	270
10.5	Enzyme Activity Assays Using MS for Screening or Confirming Drug Candidates	271
10.5.1	MS to Measure Substrate Turnover	272
10.5.2	Multiple Component Measurements	272
10.5.3	Continuous Flow Screening	272
10.5.4	Immobilized Enzyme Reactor (IMER)	273
10.5.5	Application of MALDI to High-Throughput Enzyme Assays	274
10.5.6	Ratiometric Assays Using MALDI	275
10.5.7	Self-assembled Monolayers for MALDI-MS (SAMDI)	275
10.5.8	Desorption/Ionization Process Off of Porous Silicon (DIOS) and Carbon Nanotubes	275

10.5.9	Overcoming Low Serial Throughput by Rapid Chromatography	276
10.5.10	MALDI–Triple Quadrupole Mass Spectrometry (MALDI-3Q)	276
10.6	Conclusions and Future Directions	276
	References	277
11	Utilization of Mass Spectrometry for the Structural Characterization of Biopharmaceutical Protein Products	287
	<i>Amareth Lim and Catherine A. Srebalus Barnes</i>	
11.1	Introduction	287
11.2	MS-Based Approach for the Characterization of Recombinant Therapeutic Proteins	288
11.3	Cell Culture Development	290
11.4	Purification Development	294
11.4.1	Identification of a Pyruvic Acid Modification Covalently Linked at the <i>N</i> -Terminus of a Recombinant IgG4 Fc Fusion Protein	295
11.4.2	Identification of Hinge Region Cleavage in an IgG1 Monoclonal Antibody with Two <i>N</i> -Linked Glycosylation Sites	298
11.5	Formulation Development	300
11.6	Analytical Method Development	304
11.6.1	Utilization of Partial Reduction and LC-MS to Distinguish an IgG4 Monoclonal Antibody Charge Variants That Co-elute in Cation Exchange HPLC	304
11.6.2	Development of an RP-HPLC Method for Monitoring an IgG4 Fc Fusion Protein Post-Translational Modifications	309
11.7	Confirmation of Structure/Product Comparability Assessment	311
11.8	Conclusions	313
	Acknowledgments	315
	References	315
12	Post-translationally Modified Proteins: Glycosylation, Phosphorylation, and Disulfide Bond Formation	321
	<i>Anthony Tsarbopoulos and Fotini N. Bazoti</i>	
12.1	Introduction	321
12.2	Glycosylation	322

12.2.1	MS Detection of Glycoproteins	323
12.2.2	Glycan Identification, Classification, and Heterogeneity	327
12.2.3	Glycoprotein Mapping by LC-ESI and MALDI Tandem MS	329
12.2.4	Glycosylation Site Quantitation	336
12.3	Phosphorylation	338
12.3.1	MS Detection of Phosphorylation	338
12.3.2	Enrichment of Phosphorylated Peptides and Proteins	340
12.3.3	Phosphorylation Site Identification	341
12.3.4	Phosphopeptide Quantitation	346
12.4	Disulfide Bond Detection and Mapping	347
12.4.1	MS Detection	347
12.4.2	Disulfide Mapping	347
12.5	Future Perspectives	350
	Acknowledgments	352
	Abbreviations	353
	References	354
13	Mass Spectrometry of Antigenic Peptides	371
	<i>Henry Rohrs</i>	
13.1	Introduction	371
13.1.1	Brief History of MHC Studies	371
13.1.2	Brief Introduction to Immunobiology	372
13.2	Analysis of Antigenic Peptides	374
13.2.1	MHC Peptide Analysis in Practice—Sample Preparation	376
13.2.2	MHC Peptide Analysis in Practice—HPLC Separation	377
13.2.3	MHC Peptide Analysis in Practice—Mass Spectrometers	377
13.2.4	MHC Peptide Analysis in Practice—Data Analysis	379
13.3	Examples of the Application of Mass Spectrometry to Antigenic Peptide Study	381
13.3.1	Work of D. Hunt	381
13.3.2	Work of E. Unanue	382
13.3.3	Work of H. Rammensee	384
13.3.4	Work of P. Allen	384
13.3.5	Work of P. Thibault	385
13.4	Future Work	385
	Acknowledgments	386
	Abbreviations	387
	References	387

14	Neuropeptidomics	393
	<i>Jonathan V. Sweedler, Fang Xie, and Adriana Bora</i>	
14.1	Introduction	393
14.2	Neuropeptidomics: Characterizing Peptides in the Brain	394
14.3	Sample Preparation for Mass Spectrometry	395
14.3.1	Direct Tissue Profiling	397
14.3.2	Extraction-Based Strategies	399
14.3.3	Collecting Peptide Release	400
14.3.4	Sample Preparation for MSI	403
14.4	Separations	405
14.5	Peptide Characterization via Mass Spectrometry	407
14.5.1	Qualitative Analyses	407
14.5.2	Relative Quantitative Analyses	413
14.5.3	Data Analysis with Bioinformatics	416
14.6	Conclusions	419
14.7	Future Perspectives	419
	Acknowledgments	420
	References	420
15	Mass Spectrometry for the Study of Peptide Drug Metabolism	435
	<i>Patrick J. Rudewicz</i>	
15.1	Introduction	435
15.2	Peptide Drug Metabolism	436
15.3	LC-MS/MS for Metabolite Identification	437
15.4	Quantitative Analysis	439
15.5	Case Study: IL-1 β Protease Inhibitors	440
15.6	Future Directions	445
	References	445
	INDEX	449